LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Article ; Online: Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".

Davoudi-Monfared, Effat / Khalili, Hossein

2021 Volume 65, Issue 4

MeSH term(s)	COVID-19 ; Humans ; Immunotherapy ; Interferon beta-1a ; SARS-CoV-2
Chemical Substances	Interferon beta-1a (XRO4566Q4R)
Language	English
Publishing date	2021-03-18
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	217602-6
ISSN	1098-6596 ; 0066-4804
ISSN (online)	1098-6596
ISSN	0066-4804
DOI	10.1128/AAC.00083-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 809: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Einzelsignatur: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of Famotidine on COVID-19: Killing Virus or Opposing ARDS?

Hosseini, Mahnaz Sadat / Davoudi-Monfared, Effat / Najmeddin, Farhad / Mojtahedzadeh, Mojtaba

Pulmonary therapy

2023 Volume 9, Issue 2, Page(s) 173–175

Abstract: Since the first detection of SARS-CoV-2 in China, COVID-19 (Corona Virus Disease 2019) has taken the lives of more than six million people. Although some antivirals seem proper for treatment, the investigation of finding the best therapeutic approach for ...

Abstract	Since the first detection of SARS-CoV-2 in China, COVID-19 (Corona Virus Disease 2019) has taken the lives of more than six million people. Although some antivirals seem proper for treatment, the investigation of finding the best therapeutic approach for COVID-19 is still continuing. Some observational research showed that famotidine has promising effects in addition to its acid-suppressing characteristics in the treatment of COVID-19. The definite viricidal effect of famotidine is not established. Opposing acute respiratory distress syndrome (ARDS) can be proposed as a probable mechanism for the action of famotidine, due to its inhibitory effect on histamine release, inhibition of transmembrane protease serine S (TMPRSS) and stabilizing glycocalyx. These hypotheses should be under investigation in the future.
Language	English
Publishing date	2023-04-01
Publishing country	United States
Document type	Journal Article
ISSN	2364-1746
ISSN (online)	2364-1746
DOI	10.1007/s41030-023-00220-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The effect of midodrine on lactate clearance in patients with septic shock: a pilot study.

Davoudi-Monfared, Effat / Mohammadi, Mostafa / Khoshavi, Meysam / Khalili, Hossein

Journal of comparative effectiveness research

2021 Volume 10, Issue 8, Page(s) 673–683

Abstract: Background: ...

Abstract	Background:
MeSH term(s)	Humans ; Lactic Acid ; Midodrine/therapeutic use ; Pilot Projects ; Shock, Septic/drug therapy ; Vasoconstrictor Agents/therapeutic use
Chemical Substances	Vasoconstrictor Agents ; Lactic Acid (33X04XA5AT) ; Midodrine (6YE7PBM15H)
Language	English
Publishing date	2021-04-16
Publishing country	England
Document type	Clinical Trial ; Journal Article
ZDB-ID	2669725-7
ISSN	2042-6313 ; 2042-6305
ISSN (online)	2042-6313
ISSN	2042-6305
DOI	10.2217/cer-2020-0238
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: The threat of carbapenem-resistant gram-negative bacteria in a Middle East region.

Davoudi-Monfared, Effat / Khalili, Hossein

Infection and drug resistance

2018 Volume 11, Page(s) 1831–1880

Abstract: Data on the status of carbapenem-resistant microorganisms in the Middle East countries are scarce. The aim of this review was to collect available data regarding resistance to carbapenems in a Middle East region. Available data regarding carbapenem- ... ...

Abstract	Data on the status of carbapenem-resistant microorganisms in the Middle East countries are scarce. The aim of this review was to collect available data regarding resistance to carbapenems in a Middle East region. Available data regarding carbapenem-resistant isolates were considered for evaluation in this review. Biomedical electronic databases were systematically searched to find related articles. The key terms used were "carbapenem-resistant, resistant gram-negative bacilli,
Language	English
Publishing date	2018-10-17
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2494856-1
ISSN	1178-6973
ISSN	1178-6973
DOI	10.2147/IDR.S176049
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review.

Davoudi-Monfared, Effat / Ahmadi, Arezoo / Karimpour-Razkenari, Elahe / Shahrami, Bita / Najmeddin, Farhad / Mojtahedzadeh, Mojtaba

American journal of therapeutics

2022 Volume 29, Issue 5, Page(s) e520–e533

Abstract: Background: Remdesivir (RDV) is the main antiviral for the treatment of moderate to severe forms of Coronavirus disease 2019 (COVID-19). Several studies revealed a shortening time to clinical improvement of COVID-19 and mortality benefits in patients ... ...

Abstract	Background: Remdesivir (RDV) is the main antiviral for the treatment of moderate to severe forms of Coronavirus disease 2019 (COVID-19). Several studies revealed a shortening time to clinical improvement of COVID-19 and mortality benefits in patients receiving RDV. The patients with renal disease were excluded from large clinical trials of RDV, and the probable nephrotoxicity of the drug, its metabolites, and the vehicle (sulfobutylether-β-cyclodextrin) have led to the recommendation against using RDV in patients with an estimated glomerular filtration rate of <30 mL/min. Areas of uncertainty: This systematic review aimed to collect data about the necessity and safety administration of RDV in the setting of renal impairment. Data sources: Search through databases including MEDLINE, ScienceDirect, Cochrane Library, and PubMed was performed. The studies were carried out in adults and enrolled patients with different types of renal impairment (ie, acute kidney injury, chronic kidney disease, kidney transplant, and renal replacement therapy) were included. Eligible studies were assessed, and required data were extracted. Results: Twenty-two cross-sectional studies, cohorts, case reports, and case series were included in this review. The mortality rate was between 7.3% and 50%, and various severity of COVID-19 was included in the studies. None of them reported an increase in adverse effects attributed to RDV administration. A decrease in inflammatory mediators and other benefits were obvious. Conclusions: Although the manufacturer's labeling does not recommend RDV administration in patients with severe renal impairment, it seems that nephrotoxicity is less concerning in the population of these patients. Moreover, RDV may be helpful in acute kidney injury induced by the viral invasion of COVID-19. To the best of our knowledge, this is the first systematic review of the use of RDV in kidney failure. Larger, well-designed, and pharmacokinetic studies are required to have a safe and logical recommendation about the use of RDV in patients with renal disorders.
MeSH term(s)	Acute Kidney Injury ; Adenosine Monophosphate/analogs & derivatives ; Adult ; Alanine/analogs & derivatives ; Antiviral Agents/adverse effects ; COVID-19/drug therapy ; Cross-Sectional Studies ; Humans ; Renal Insufficiency, Chronic
Chemical Substances	Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
Language	English
Publishing date	2022-07-22
Publishing country	United States
Document type	Journal Article ; Systematic Review
ZDB-ID	1280786-2
ISSN	1536-3686 ; 1075-2765
ISSN (online)	1536-3686
ISSN	1075-2765
DOI	10.1097/MJT.0000000000001543
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4351: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia: a comment.

Davoudi-Monfared, Effat / Taghizadeh-Ghehi, Maryam

International journal of clinical pharmacy

2019 Volume 41, Issue 3, Page(s) 621–622

MeSH term(s)	Colistin ; Cost-Benefit Analysis ; Drug Resistance, Multiple, Bacterial ; Humans ; Pneumonia ; Saudi Arabia
Chemical Substances	Colistin (Z67X93HJG1)
Language	English
Publishing date	2019-04-09
Publishing country	Netherlands
Document type	Letter ; Comment
ZDB-ID	2601204-2
ISSN	2210-7711 ; 2210-7703 ; 0928-1231
ISSN (online)	2210-7711
ISSN	2210-7703 ; 0928-1231
DOI	10.1007/s11096-019-00822-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Management of a critically ill patient with COVID-19-related fulminant myocarditis: A case report.

Shahrami, Bita / Davoudi-Monfared, Effat / Rezaie, Zahra / Gheibi, Shayesteh / Vakili-Ardabili, Ayda / Arabzadeh, Amir Ahmad / Talebi, Ali / Mojtahedzadeh, Mojtaba

Respiratory medicine case reports

2022 Volume 36, Page(s) 101611

Abstract: A 78-year-old man with COVID-19 infection was admitted. Initial echocardiography indicated left ventricular ejection fraction (LVEF) of 15%, high pulmonary arterial pressure, severe left ventricular dysfunction, mild diastolic dysfunction, mild ... ...

Abstract	A 78-year-old man with COVID-19 infection was admitted. Initial echocardiography indicated left ventricular ejection fraction (LVEF) of 15%, high pulmonary arterial pressure, severe left ventricular dysfunction, mild diastolic dysfunction, mild regurgitation mitral valve, and normal septal thickness. Considering the probable diagnosis of COVID-19-related myocarditis, the patient was early managed with the antivirals, immunomodulatory agents, a high dose of ascorbic acid, melatonin, and immunoglobulin therapy. His clinical condition was improved and his last echocardiography revealed LVEF of 40% and improvement in systolic and diastolic dysfunction. The clinicians should be aware of the potentially lethal cardiac complication of COVID-19, especially in geriatrics.
Language	English
Publishing date	2022-02-18
Publishing country	England
Document type	Case Reports
ZDB-ID	2666110-X
ISSN	2213-0071
ISSN	2213-0071
DOI	10.1016/j.rmcr.2022.101611
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: A Case Series of Severe Hyperammonemia Encephalopathy Related to Valproate: Can Antipsychotics Increase the Risk?

Davoudi-Monfared, Effat / Radmehr, Mojan / Ghaeli, Padideh / Mousavi, Maryam

Iranian journal of psychiatry

2019 Volume 14, Issue 3, Page(s) 248–252

Abstract: Valproate-induced hyperammonemia is a common side effect of valproate, which may occur either without any symptoms or may rarely cause symptoms of encephalopathy. Different risk factors have been defined for this side effect, including some nutritional ... ...

Abstract	Valproate-induced hyperammonemia is a common side effect of valproate, which may occur either without any symptoms or may rarely cause symptoms of encephalopathy. Different risk factors have been defined for this side effect, including some nutritional deficiencies and polypharmacy (eg, other anticonvulsants). Three cases with psychiatric disorder who showed symptoms of severe hyperammonemia encephalopathy and had taken valproate with antipsychotics, especially risperidone, are presented here. In all cases, the symptoms were improved by discontinuation of valproate. Administration of antipsychotic may be considered as a risk factor for hyperammonemic encephalopathy related to valproate, specifically in some prone populations.
Language	English
Publishing date	2019-09-25
Publishing country	Iran
Document type	Journal Article
ZDB-ID	2388800-3
ISSN	2008-2215 ; 1735-4587
ISSN (online)	2008-2215
ISSN	1735-4587
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.

Davoudi-Monfared, Effat / Rahmani, Hamid / Khalili, Hossein / Hajiabdolbaghi, Mahboubeh / Salehi, Mohamadreza / Abbasian, Ladan / Kazemzadeh, Hossein / Yekaninejad, Mir Saeed

Antimicrobial agents and chemotherapy

2020 Volume 64, Issue 9

Abstract: To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and safety of IFN β-1a were evaluated in patients with severe COVID-19. ...

Abstract	To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and safety of IFN β-1a were evaluated in patients with severe COVID-19. Forty-two patients in the interferon group received IFN β-1a in addition to the national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir). Each 44-μg/ml (12 million IU/ml) dose of interferon β-1a was subcutaneously injected three times weekly for two consecutive weeks. The control group consisted of 39 patients who received only the national protocol medications. The primary outcome of the study was time to reach clinical response. Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization. Between 29 February and 3 April 2020, 92 patients were recruited, and a total of 42 patients in the IFN group and 39 patients in the control group completed the study. As the primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 ± 5.8 versus 8.3 ± 4.9 days, respectively,
MeSH term(s)	Adult ; Aged ; Antiviral Agents/therapeutic use ; Atazanavir Sulfate/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; COVID-19 ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/immunology ; Cardiovascular Diseases/mortality ; Cardiovascular Diseases/virology ; Comorbidity ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Coronavirus Infections/virology ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus/immunology ; Diabetes Mellitus/mortality ; Diabetes Mellitus/virology ; Drug Administration Schedule ; Drug Combinations ; Drug Therapy, Combination ; Dyslipidemias/drug therapy ; Dyslipidemias/immunology ; Dyslipidemias/mortality ; Dyslipidemias/virology ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Intensive Care Units ; Interferon beta-1a/therapeutic use ; Length of Stay ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/mortality ; Neoplasms/virology ; Pandemics ; Patient Safety ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Pneumonia, Viral/virology ; Ritonavir/therapeutic use ; SARS-CoV-2 ; Survival Analysis ; Treatment Outcome
Chemical Substances	Antiviral Agents ; Drug Combinations ; lopinavir-ritonavir drug combination ; Lopinavir (2494G1JF75) ; Atazanavir Sulfate (4MT4VIE29P) ; Hydroxychloroquine (4QWG6N8QKH) ; Ritonavir (O3J8G9O825) ; Interferon beta-1a (XRO4566Q4R)
Keywords	covid19
Language	English
Publishing date	2020-08-20
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	217602-6
ISSN	1098-6596 ; 0066-4804
ISSN (online)	1098-6596
ISSN	0066-4804
DOI	10.1128/AAC.01061-20
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 809: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Einzelsignatur: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial.

Toroghi, Negar / Abbasian, Ladan / Nourian, Anahid / Davoudi-Monfared, Effat / Khalili, Hossein / Hasannezhad, Malihe / Ghiasvand, Fereshteh / Jafari, Sirous / Emadi-Kouchak, Hamid / Yekaninejad, Mir Saeed

Pharmacological reports : PR

2021 Volume 74, Issue 1, Page(s) 229–240

Abstract: Background and objectives: Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients ...

Abstract	Background and objectives: Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients with a diagnosis of moderate to severe COVID-19. Methods: Hospitalized patients with a diagnosis of moderate to severe COVID-19 were assigned to intravenous low-dose (8 mg once daily), intermediate-dose (8 mg twice daily) or high-dose (8 mg thrice daily) dexamethasone for up to 10 days or until hospital discharge. Clinical response, 60-day survival and adverse effects were the main outcomes of the study. Results: In the competing risk survival analysis, patients in the low-dose group had a higher clinical response than the high-dose group when considering death as a competing risk (HR = 2.03, 95% CI: 1.23-3.33, p = 0.03). Also, the survival was significantly longer in the low-dose group than the high-dose group (HR = 0.36, 95% CI = 0.15-0.83, p = 0.02). Leukocytosis and hyperglycemia were the most common side effects of dexamethasone. Although the incidence was not significantly different between the groups, some adverse effects were numerically higher in the intermediate-dose and high-dose groups than in the low-dose group. Conclusions: Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31).
MeSH term(s)	Adult ; Aged ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; COVID-19/drug therapy ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Dexamethasone/therapeutic use ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Humans ; Hyperglycemia/chemically induced ; Incidence ; Leukocytosis/chemically induced ; Male ; Middle Aged ; Survival Analysis ; Treatment Outcome
Chemical Substances	Anti-Inflammatory Agents ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2021-11-27
Publishing country	Switzerland
Document type	Comparative Study ; Journal Article ; Randomized Controlled Trial
ZDB-ID	2186248-5
ISSN	1734-1140
ISSN	1734-1140
DOI	10.1007/s43440-021-00341-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 861: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito